NASDAQ:RXRX

Recursion Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy RXRX

*Your capital is at risk

$3.22

+0.0400 (+1.26%)

At Close: Aug 07, 2026

Recursion Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -31.72. In total, the insiders bought 4.89M and sold 2.43M RXRX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-31.72
● Buy	4.89M shares
● Sell	2.43M shares
39% Buy Activity Negligible or No Correlation
Buy Signal Low Confidence Feb 06, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory negative Insider Power Score of -31.72. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Mar 03, 2026 Sell	Class A Common Stock S-Sale	Borgeson Blake Director	Director	170 000 Value: $588.2K
Feb 19, 2026 Sell	Class A Common Stock S-Sale	Gibson Christopher Director	Director	40 000 Value: $138.4K
Feb 19, 2026 Buy	Class A Common Stock C-Conversion	Gibson Christopher Director	Director	40 000 Value: $148.8K
Feb 19, 2026 Sell	Class B Common Stock C-Conversion	Gibson Christopher Director	Director	40 000 Value: $0
Feb 18, 2026 Sell	Class A Common Stock S-Sale	Taylor Ben R Chief Financial Officer	C-Suite Officer	13 426 Value: $41.4K
Feb 17, 2026 Sell	Class A Common Stock F-InKind	Gibson Christopher Director	Director	27 265 Value: $95.2K
Feb 17, 2026 Sell	Class A Common Stock F-InKind	Hallett David Chief Scientific Officer	Officer	11 908 Value: $41.6K
Feb 17, 2026 Sell	Class A Common Stock F-InKind	Taylor Ben R Chief Financial Officer	C-Suite Officer	11 908 Value: $41.6K
Feb 17, 2026 Sell	Class A Common Stock F-InKind	Khan Najat CEO And President	CEO / President	14 280 Value: $49.8K
Feb 06, 2026 Buy	Class A Common Stock A-Award	Khan Najat CEO And President	CEO / President	30 346 Value: $120.8K
Feb 06, 2026 Sell	Class A Common Stock F-InKind	Khan Najat CEO And President	CEO / President	10 364 Value: $41.2K
Feb 06, 2026 Buy	Class A Common Stock A-Award	Khan Najat CEO And President	CEO / President	1 673 546 Value: $6.66M
Feb 06, 2026 Buy	Class A Common Stock A-Award	Taylor Ben R Chief Financial Officer	C-Suite Officer	24 254 Value: $96.5K
Feb 06, 2026 Sell	Class A Common Stock F-InKind	Taylor Ben R Chief Financial Officer	C-Suite Officer	11 400 Value: $45.4K
Feb 06, 2026 Buy	Class A Common Stock A-Award	Taylor Ben R Chief Financial Officer	C-Suite Officer	446 279 Value: $1.78M
Feb 06, 2026 Buy	Class A Common Stock A-Award	Hallett David Chief Scientific Officer	Officer	24 254 Value: $96.5K
Feb 06, 2026 Sell	Class A Common Stock F-InKind	Hallett David Chief Scientific Officer	Officer	11 400 Value: $45.4K
Feb 06, 2026 Buy	Class A Common Stock A-Award	Hallett David Chief Scientific Officer	Officer	502 064 Value: $2.00M
Feb 06, 2026 Sell	Class A Common Stock F-InKind	Gibson Christopher Director	Director	10 364 Value: $36.9K
Feb 06, 2026 Buy	Class A Common Stock A-Award	Gibson Christopher Director	Director	30 346 Value: $120.8K
Feb 04, 2026 Sell	Class A Common Stock S-Sale	Gibson Christopher Director	Director	40 000 Value: $164.8K
Feb 04, 2026 Buy	Class A Common Stock C-Conversion	Gibson Christopher Director	Director	40 000 Value: $156.0K
Feb 04, 2026 Sell	Class B Common Stock C-Conversion	Gibson Christopher Director	Director	40 000 Value: $0
Feb 03, 2026 Sell	Class A Common Stock S-Sale	Borgeson Blake Director	Director	220 000 Value: $924.0K
Jan 20, 2026 Sell	Class A Common Stock S-Sale	Gibson Christopher Director	Director	40 000 Value: $178.8K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT RECURSION PHARMACEUTICALS, INC.

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial...

Read Full Profile Here